{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:26:30Z","timestamp":1786112790820,"version":"build-2736575974"},"reference-count":128,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP230419"],"award-info":[{"award-number":["RP230419"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP210180"],"award-info":[{"award-number":["RP210180"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP250567"],"award-info":[{"award-number":["RP250567"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014108","name":"University of Texas Rio Grande Valley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["SC1GM139727"],"award-info":[{"award-number":["SC1GM139727"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U54MD019970"],"award-info":[{"award-number":["U54MD019970"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["SC1GM139727"],"award-info":[{"award-number":["SC1GM139727"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54MD019970"],"award-info":[{"award-number":["U54MD019970"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.drudis.2026.104666","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:21:10Z","timestamp":1775809270000},"page":"104666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Scope of nanobodies in hepatopancreatobiliary oncology"],"prefix":"10.1016","volume":"31","author":[{"given":"Upendra","family":"Nayek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tusha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek K.","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikanth","family":"Gadad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-8828","authenticated-orcid":false,"given":"Murali M.","family":"Yallapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everardo","family":"Cobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash C.","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104666_b0005","doi-asserted-by":"crossref","first-page":"15286","DOI":"10.1016\/S0021-9258(18)77254-2","article-title":"Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin","volume":"265","author":"Gendler","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104666_b0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.18632\/oncotarget.4539","article-title":"Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies","volume":"6","author":"Brandi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104666_b0015","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.drudis.2026.104666_b0020","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.3390\/cancers16193431","article-title":"Honey targets ribosome biogenesis components to suppress the growth of human pancreatic cancer cells","volume":"16","author":"Bangash","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2026.104666_b0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13046-018-1009-7","article-title":"Therapeutic efficacy of a novel \u03b2III\/\u03b2IV-tubulin inhibitor (VERU-111) in pancreatic cancer","volume":"38","author":"Kashyap","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104666_b0030","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.biomaterials.2015.02.082","article-title":"Nanoparticle formulation of ormeloxifene for pancreatic cancer","volume":"53","author":"Khan","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2026.104666_b0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/cells9010103","article-title":"Novel mechanistic insight into the anticancer activity of cucurbitacin D against pancreatic cancer (Cuc D attenuates pancreatic cancer)","volume":"9","author":"Sikander","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2026.104666_b0040","article-title":"Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment","volume":"20","author":"Massey","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2026.104666_b0045","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.3390\/ijms21103586","article-title":"APE1 promotes pancreatic cancer proliferation through GFR\u03b11\/Src\/ERK axis-cascade signaling in response to GDNF","volume":"21","author":"Choi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104666_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100951","article-title":"Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma","volume":"47","author":"Afaq","year":"2024","journal-title":"Neoplasia"},{"key":"10.1016\/j.drudis.2026.104666_b0055","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1158\/0008-5472.CAN-13-1288","article-title":"Targeting microRNAs in pancreatic cancer: microplayers in the big game","volume":"73","author":"Khan","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104666_b0060","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s42003-022-04102-4","article-title":"Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore","volume":"5","author":"Chaib","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.drudis.2026.104666_b0065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/1535-7163.MCT-11-0598","article-title":"MUC13 mucin augments pancreatic tumorigenesis","volume":"11","author":"Chauhan","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104666_b0070","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104666_b0075","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.drudis.2026.104666_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.01.045","article-title":"Research trends in the use of nanobodies for cancer therapy","volume":"381","author":"Hou","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104666_b0085","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ilar.46.3.258","article-title":"Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources","volume":"46","author":"Lipman","year":"2005","journal-title":"ILAR J"},{"key":"10.1016\/j.drudis.2026.104666_b0090","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s40265-018-0989-0","article-title":"Caplacizumab: first global approval","volume":"78","author":"Duggan","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104666_b0095","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2017.14545","article-title":"Monobodies as possible next-generation protein therapeutics\u2014a perspective","volume":"147","author":"Hantschel","year":"2017","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.drudis.2026.104666_b0100","doi-asserted-by":"crossref","first-page":"7882","DOI":"10.1021\/acs.jafc.6b02978","article-title":"Phage-mediated immuno-PCR for ultrasensitive detection of Cry1Ac protein based on nanobody","volume":"64","author":"Liu","year":"2016","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.drudis.2026.104666_b0105","unstructured":"Sanmamed MF et al. Safety, feasibility, and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4-1BB) mAb urelumab in combination with nivolumab."},{"key":"10.1016\/j.drudis.2026.104666_b0110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.vetimm.2008.10.299","article-title":"Camelid immunoglobulins and nanobody technology","volume":"128","author":"Muyldermans","year":"2009","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.drudis.2026.104666_b0115","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1021\/bi0009082","article-title":"Thermal unfolding of a llama antibody fragment: a two-state reversible process","volume":"40","author":"P\u00e9rez","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2026.104666_b0120","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1110\/ps.34602","article-title":"Single\u2010domain antibody fragments with high conformational stability","volume":"11","author":"Dumoulin","year":"2002","journal-title":"Protein Sci"},{"key":"10.1016\/j.drudis.2026.104666_b0125","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/s42256-025-01131-6","article-title":"Predicting the conformational flexibility of antibody and T cell receptor complementarity-determining regions","volume":"7","author":"Spoendlin","year":"2025","journal-title":"Nat Mach Intell"},{"key":"10.1016\/j.drudis.2026.104666_b0130","doi-asserted-by":"crossref","first-page":"14405","DOI":"10.3390\/ijms232214405","article-title":"Modular site-specific conjugation of nanobodies using two co-associating tags","volume":"23","author":"Moeglin","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104666_b0135","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1074\/jbc.M114.617787","article-title":"Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1","volume":"290","author":"Steeland","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104666_b0140","doi-asserted-by":"crossref","first-page":"D1273","DOI":"10.1093\/nar\/gkab1021","article-title":"INDI\u2014integrated nanobody database for immunoinformatics","volume":"50","author":"Deszy\u0144ski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2026.104666_b0145","first-page":"1335","article-title":"In vitro combination therapy of pathologic angiogenesis using anti-vascular endothelial growth factor and anti-neuropilin-1 nanobodies","volume":"23","author":"Mohseni","year":"2020","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.drudis.2026.104666_b0150","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1038\/sj.emboj.7601744","article-title":"Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS","volume":"26","author":"Tanaka","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2026.104666_b0155","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1084\/jem.20071155","article-title":"Heavy chain-only antibodies are spontaneously produced in light chain-deficient mice","volume":"204","author":"Zou","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2026.104666_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbt.2018.08.002","article-title":"Antibody validation: a view from the mountains","volume":"45","author":"Taussig","year":"2018","journal-title":"N Biotechnol"},{"key":"10.1016\/j.drudis.2026.104666_b0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molimm.2021.01.010","article-title":"Identification of nanobodies against hepatocellular carcinoma marker glypican-3","volume":"131","author":"Wang","year":"2021","journal-title":"Mol Immunol"},{"key":"10.1016\/j.drudis.2026.104666_b0170","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41522-026-00916-w","article-title":"Lactobacillus-vectored nanobodies improve broiler productivity under sub-clinical necrotic enteritis with associated microbiome and transcriptome changes","volume":"12","author":"Hall","year":"2026","journal-title":"npj Biofilms Microbiomes"},{"key":"10.1016\/j.drudis.2026.104666_b0175","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1038\/s41467-020-19884-6","article-title":"A nanobody suite for yeast scaffold nucleoporins provides details of the nuclear pore complex structure","volume":"11","author":"Nordeen","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104666_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1005800","article-title":"Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors","volume":"13","author":"Hambach","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104666_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217934","article-title":"A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment","volume":"632","author":"Chen","year":"2025","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2026.104666_b0190","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s13205-018-1500-z","article-title":"Transient expression of anti-VEFGR2 nanobody in Nicotiana tabacum and N. benthamiana","volume":"8","author":"Modarresi","year":"2018","journal-title":"3 Biotech"},{"key":"10.1016\/j.drudis.2026.104666_b0195","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1472-6750-12-59","article-title":"Rotavirus A-specific single-domain antibodies produced in baculovirus-infected insect larvae are protective in vivo","volume":"12","author":"G\u00f3mez-Sebasti\u00e1n","year":"2012","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.drudis.2026.104666_b0200","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1166\/jbn.2021.3098","article-title":"Application of molecular nanoprobes in the analysis of differentially expressed genes and prognostic models of primary hepatocellular carcinoma","volume":"17","author":"Luo","year":"2021","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/j.drudis.2026.104666_b0205","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.bbrc.2020.06.097","article-title":"In vitro affinity maturation to improve the efficacy of a hypoxia-inducible factor 1\u03b1 single-domain intrabody","volume":"529","author":"Hu","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2026.104666_b0210","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.2147\/IJN.S235058","article-title":"Preparation and characterization of anti-GPC3 nanobody against hepatocellular carcinoma","volume":"15","author":"Xia","year":"2020","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.drudis.2026.104666_b0215","first-page":"189","article-title":"A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy","volume":"8","author":"Wang","year":"2025","journal-title":"Antib Ther"},{"key":"10.1016\/j.drudis.2026.104666_b0220","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2967\/jnumed.120.255679","article-title":"Phase I trial of (131)I-GMIB-anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients","volume":"62","author":"D\u2019Huyvetter","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.drudis.2026.104666_b0225","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.32604\/or.2025.065319","article-title":"Emerging HER2 targeting immunotherapy for cholangiocarcinoma","volume":"33","author":"Sungwan","year":"2025","journal-title":"Oncol Res"},{"key":"10.1016\/j.drudis.2026.104666_b0230","article-title":"HER2-targeted therapy combined with multidisciplinary management in advanced gallbladder cancer: a case report with 90-month survival","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104666_b0235","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s00259-025-07087-4","article-title":"Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography","volume":"52","author":"He","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.drudis.2026.104666_b0240","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12943-025-02325-7","article-title":"Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation","volume":"24","author":"Yi","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2026.104666_b0245","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1038\/s41598-019-38988-8","article-title":"Antibodies to a CA 19-9 related antigen complex identify SOX9 expressing progenitor cells in human foetal pancreas and pancreatic adenocarcinoma","volume":"9","author":"Farley","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104666_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.885424","article-title":"Development of a humanized VHH based recombinant antibody targeting Claudin 18.2 positive cancers","volume":"13","author":"Zhong","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104666_b0255","article-title":"Bispecific antibody PD-L1 x CD3 boosts the anti-tumor potency of the expanded V\u03b32V\u03b42 T cells","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104666_b0260","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"CiteJavle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104666_b0265","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012344","article-title":"Phase Ib multicenter study of anti-TIM-3 (S095018\/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced\/metastatic recurrent biliary tract cancer","volume":"14","author":"Ghiringhelli","year":"2026","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.drudis.2026.104666_b0270","article-title":"Receipt of curative resection or palliative care for hepatopancreaticobiliary tumours (RICOCHET): protocol for a nationwide collaborative observational study","volume":"8","author":"RICOCHET Study Group 1","year":"2019","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.drudis.2026.104666_b0275","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41388-018-0517-4","article-title":"An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC","volume":"38","author":"Yonesaka","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104666_b0280","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12951-023-02183-9","article-title":"TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer","volume":"21","author":"Xu","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.drudis.2026.104666_b0285","article-title":"Site-selective tyrosine reaction for antibody-cell conjugation and targeted immunotherapy","volume":"11","author":"Chen","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"10.1016\/j.drudis.2026.104666_b0290","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.1002\/mco2.557","article-title":"Half-life extension of single-domain antibody-drug conjugates by albumin binding moiety enhances antitumor efficacy","volume":"2024","author":"Li","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.drudis.2026.104666_b0295","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ijbiomac.2022.01.056","article-title":"Generation of a nanobody-alkaline phosphatase heptamer fusion for ratiometric fluorescence immunodetection of trace alpha fetoprotein in serum","volume":"201","author":"Su","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2026.104666_b0300","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.omto.2022.02.015","article-title":"A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer","volume":"24","author":"Li","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.drudis.2026.104666_b0305","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jcyt.2024.02.024","article-title":"Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments","volume":"26","author":"Nix","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.drudis.2026.104666_b0310","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s12967-024-05101-1","article-title":"The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment","volume":"22","author":"Xiong","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.drudis.2026.104666_b0315","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1158\/1078-0432.CCR-14-1170","article-title":"Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma","volume":"20","author":"Gao","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104666_b0320","doi-asserted-by":"crossref","first-page":"e0022","DOI":"10.1097\/HC9.0000000000000022","article-title":"Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC","volume":"7","author":"Kolluri","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.drudis.2026.104666_b0325","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1217868110","article-title":"Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma","volume":"110","author":"Feng","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104666_b0330","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41392-025-02219-6","article-title":"N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104666_b0335","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/s41467-023-37616-4","article-title":"The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104666_b0340","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s41401-020-00574-4","article-title":"Development of a nanobody-based immunoassay for the sensitive detection of fibrinogen-like protein 1","volume":"42","author":"Zhang","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2026.104666_b0345","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/2326-6066.CIR-17-0495","article-title":"Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1-specific VHHs","volume":"6","author":"Dougan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.drudis.2026.104666_b0350","doi-asserted-by":"crossref","first-page":"8649","DOI":"10.3390\/ijms26178649","article-title":"A study on the efficacy and pharmacological mechanism of liposome complexes containing STING agonist and anti-PD-L1 nanobody in inhibiting HCC","volume":"26","author":"Wang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104666_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216760","article-title":"Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb\/CD3 BsAb","volume":"588","author":"Zhang","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2026.104666_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120647","article-title":"Preclinical evaluation of a novel anti-mesothelin immunotoxin based on a single domain antibody as the targeting ligand","volume":"602","author":"Li","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104666_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111944","article-title":"The nanobody targeting PD-L1 and CXCR4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment","volume":"132","author":"Li","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2026.104666_b0370","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1186\/s12885-022-10165-7","article-title":"Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4","volume":"22","author":"Hao","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drudis.2026.104666_b0375","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1021\/acs.molpharmaceut.5c00430","article-title":"Development of [18F] AlF-RESCA-H006 as a novel molecular probe for 5T4 tumor imaging and exploration of its application in pancreatic adenocarcinoma","volume":"22","author":"Kong","year":"2025","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104666_b0380","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11307-015-0909-6","article-title":"Hypoxia-targeting fluorescent nanobodies for optical molecular imaging of pre-invasive breast cancer","volume":"18","author":"van Brussel","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.drudis.2026.104666_b0385","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s44321-024-00059-5","article-title":"ImmunoPET imaging of Trop2 in patients with solid tumours","volume":"16","author":"Huang","year":"2024","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.drudis.2026.104666_b0390","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1021\/acscentsci.5b00121","article-title":"Use of 18F-2-fluorodeoxyglucose to label antibody fragments for immuno-positron emission tomography of pancreatic cancer","volume":"1","author":"Rashidian","year":"2015","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.drudis.2026.104666_b0395","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1021\/acs.molpharmaceut.5c00041","article-title":"68Ga-NOTA-m-SNA006: a next-generation CD8-targeting nanobody probe to enhance renal and hepatic clearance in noninvasive immunoPET imaging","volume":"22","author":"Peng","year":"2025","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104666_b0400","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00259-024-06985-3","article-title":"Radioiodinated nanobody immunoPET probe for in vivo detection of CD147 in pan-cancer","volume":"52","author":"Ma","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.drudis.2026.104666_b0405","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00259-025-07441-6","article-title":"ImmunoPET imaging of c-Met using a nanobody-based tracer [68Ga] Ga-NOTA-PFCM01 in pancreatic ductal adenocarcinoma models and non-human primates","volume":"53","author":"Sun","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.drudis.2026.104666_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118319","article-title":"Engineered B7-H3-targeted VHH-fc fusion antibody demonstrates rapid tumor accumulation for infrared imaging in pancreatic cancer xenograft model","volume":"129","author":"Mo","year":"2025","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104666_b0415","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2967\/jnumed.122.265171","article-title":"Site-specifically conjugated single-domain antibody successfully identifies glypican-3-expressing liver cancer by immuno-PET","volume":"64","author":"Fayn","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.drudis.2026.104666_b0420","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.123.266381","article-title":"Preclinical evaluation of a radiotheranostic single-domain antibody against fibroblast activation protein \u03b1","volume":"64","author":"Dekempeneer","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.drudis.2026.104666_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.109537","article-title":"Fluorescent nanobodies for enhanced guidance in digestive tumors and liver metastasis surgery","volume":"51","author":"Mateusiak","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.drudis.2026.104666_b0430","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3390\/biom12050711","article-title":"Fluorescent anti-CEA nanobody for rapid tumor-targeting and imaging in mouse models of pancreatic cancer","volume":"12","author":"Lwin","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2026.104666_b0435","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3390\/biom13040618","article-title":"Near-infrared fluorescence imaging of pancreatic cancer using a fluorescently labeled anti-CEA nanobody probe: a preclinical study","volume":"13","author":"van Manen","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2026.104666_b0440","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.surg.2020.02.020","article-title":"Tumor-specific near-infrared nanobody probe rapidly labels tumors in an orthotopic mouse model of pancreatic cancer","volume":"168","author":"Lwin","year":"2020","journal-title":"Surgery"},{"issue":"8","key":"10.1016\/j.drudis.2026.104666_bib636","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1021\/acs.jpca.0c00009","article-title":"Thermal energy electrons and OH-radicals induce strand breaks in DNA in an aqueous environment: Some salts offer protection against strand breaks","volume":"124","author":"Nayek","year":"2020","journal-title":"J Phys Chem A"},{"key":"10.1016\/j.drudis.2026.104666_b0445","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1021\/acsnano.3c07002","article-title":"Precise photodynamic therapy by midkine nanobody-engineered nanoparticles remodels the microenvironment of pancreatic ductal adenocarcinoma and potentiates the immunotherapy","volume":"18","author":"Qu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2026.104666_b0450","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1158\/1535-7163.MCT-12-1227","article-title":"Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment","volume":"12","author":"Yallapu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104666_b0455","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.nucmedbio.2022.09.001","article-title":"Biologicals as theranostic vehicles in paediatric oncology","volume":"114\u2013115","author":"Niessen","year":"2022","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.drudis.2026.104666_b0460","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejpb.2017.12.009","article-title":"The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates","volume":"124","author":"van Lith","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.drudis.2026.104666_b0465","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.nano.2013.12.007","article-title":"Nanobody\u2013photosensitizer conjugates for targeted photodynamic therapy","volume":"10","author":"Heukers","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2026.104666_b0470","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/cancers13030428","article-title":"Site-specific dual-labeling of a VHH with a chelator and a photosensitizer for nuclear imaging and targeted photodynamic therapy of EGFR-positive tumors","volume":"13","author":"Renard","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104666_b0475","article-title":"Bispecific nanobody\u2010aptamer conjugates for enhanced cancer therapy in solid tumors","volume":"20","author":"Wang","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.drudis.2026.104666_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2026.102688","article-title":"A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer","author":"Ning","year":"2026","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.drudis.2026.104666_b0485","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41401-022-01020-3","article-title":"Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1\/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody","volume":"44","author":"Jia","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2026.104666_b0490","article-title":"mRNA delivery of a bispecific single\u2010domain antibody to polarize tumor\u2010associated macrophages and synergize immunotherapy against liver malignancies","volume":"33","author":"Wang","year":"2021","journal-title":"Adv Mater"},{"key":"10.1016\/j.drudis.2026.104666_b0495","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12943-025-02253-6","article-title":"Transient intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in cancer cells inspires long-term T cell activation and infiltration to combat tumor and inhibit cancer metastasis","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2026.104666_b0500","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104666_b0505","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1038\/s41388-024-03066-5","article-title":"Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4","volume":"43","author":"Zeng","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104666_b0510","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12575-021-00147-7","article-title":"Recent advances on immune targeted therapy of colorectal cancer using bi-specific antibodies and therapeutic vaccines","volume":"23","author":"Azadi","year":"2021","journal-title":"Biol Proced Online"},{"key":"10.1016\/j.drudis.2026.104666_b0515","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12951-021-00768-w","article-title":"Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein","volume":"19","author":"Lu","year":"2021","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.drudis.2026.104666_b0520","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12951-022-01619-y","article-title":"A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA. 1 through a unique binding mode","volume":"20","author":"Zhao","year":"2022","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.drudis.2026.104666_b0525","doi-asserted-by":"crossref","first-page":"20565","DOI":"10.1073\/pnas.1012865107","article-title":"CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells","volume":"107","author":"J\u00e4hnichen","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104666_b0530","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41467-018-07195-w","article-title":"A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity","volume":"9","author":"Compte","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104666_b0535","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202400428","article-title":"Lactobacillus reuteri assists engineered bacteria that target tumors to release PD\u2010L1nb to mitigate the adverse effects of breast cancer immunotherapy","volume":"19","author":"Yue","year":"2024","journal-title":"Biotechnol J"},{"key":"10.1016\/j.drudis.2026.104666_b0540","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/hep.30949","article-title":"Engineered anti\u2010GPC3 immunotoxin, HN3\u2010ABD\u2010T20, produces regression in mouse liver cancer xenografts through prolonged serum retention","volume":"71","author":"Fleming","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2026.104666_b0545","doi-asserted-by":"crossref","first-page":"6536","DOI":"10.1038\/ncomms7536","article-title":"Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis","volume":"6","author":"Gao","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104666_b0550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285964","article-title":"Development and characterization of nanobodies that specifically target the oncogenic Phosphatase of Regenerating Liver-3 (PRL-3) and impact its interaction with a known binding partner, CNNM3","volume":"18","author":"Smith","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104666_b0555","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/1535-7163.MCT-23-0614","article-title":"Co-blocking TIGIT and PVRIG using a novel bispecific antibody enhances antitumor immunity","volume":"24","author":"Lin","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104666_b0560","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202208773","article-title":"Chemoenzymatic synthesis of a rhamnose\u2010functionalized bispecific nanobody as a bispecific antibody mimic for cancer immunotherapy","volume":"61","author":"Hong","year":"2022","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.drudis.2026.104666_b0565","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1038\/s41598-017-02483-9","article-title":"Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors","volume":"7","author":"Zhu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104666_b0570","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12951-022-01456-z","article-title":"A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease","volume":"20","author":"Hu","year":"2022","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.drudis.2026.104666_b0575","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1016\/j.apsb.2024.04.003","article-title":"Exosomes derived from tumor adjacent fibroblasts efficiently target pancreatic tumors","volume":"14","author":"Setua","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104666_b0580","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/IJN.S388916","article-title":"Surface engineering of HEK293 cell-derived extracellular vesicles for improved pharmacokinetic profile and targeted delivery of IL-12 for the treatment of hepatocellular carcinoma","volume":"18","author":"Zhang","year":"2023","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.drudis.2026.104666_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2023.341840","article-title":"Development of a highly sensitive immunoassay based on pentameric nanobodies for carcinoembryonic antigen detection","volume":"1279","author":"Gu","year":"2023","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.drudis.2026.104666_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.142667","article-title":"Designed peptide binders and nanobodies as PROTAC starting points for targeted degradation of PCNA and BCL6","volume":"308","author":"Zhao","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2026.104666_b0595","doi-asserted-by":"crossref","first-page":"772","DOI":"10.20892\/j.issn.2095-3941.2020.0568","article-title":"VHH212 nanobody targeting the hypoxia-inducible factor 1\u03b1 suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo","volume":"18","author":"Kang","year":"2021","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.drudis.2026.104666_b0600","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ejca.2012.07.019","article-title":"Single domain antibody against carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) inhibits proliferation, migration, invasion and angiogenesis of pancreatic cancer cells","volume":"50","author":"Cheng","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.drudis.2026.104666_b0605","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jare.2023.02.013","article-title":"CEACAM7 expression contributes to early events of pancreatic cancer","volume":"55","author":"Dhasmana","year":"2024","journal-title":"J Adv Res"},{"key":"10.1016\/j.drudis.2026.104666_b0610","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/PAI.0000000000000488","article-title":"Modified nanoantibodies increase sensitivity in avidin-biotin immunohistochemistry","volume":"26","author":"Wong","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.drudis.2026.104666_b0615","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/pharmaceutics11110574","article-title":"Gemcitabine combination nano therapies for pancreatic cancer","volume":"11","author":"Samanta","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104666_b0620","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.biomaterials.2019.04.005","article-title":"Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer","volume":"208","author":"Khan","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2026.104666_b0625","doi-asserted-by":"crossref","first-page":"8982","DOI":"10.1021\/acsomega.0c00793","article-title":"Novel paclitaxel nanoformulation impairs de novo lipid synthesis in pancreatic cancer cells and enhances gemcitabine efficacy","volume":"5","author":"Shetty","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.drudis.2026.104666_b0630","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1039\/D5NH00283D","article-title":"Small but mighty: the versatility of nanobodies in modern medicine","volume":"10","author":"Blueggel","year":"2025","journal-title":"Nanoscale Horiz"},{"key":"10.1016\/j.drudis.2026.104666_b0635","doi-asserted-by":"crossref","DOI":"10.1142\/S1793545825410019","article-title":"Recombinant PASylated nanobody probes with improved blood circulation and tumor targeting","volume":"18","author":"Yang","year":"2025","journal-title":"J Innov Opt Health Sci"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:14:30Z","timestamp":1785946470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":128,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1359644626000711"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104666","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scope of nanobodies in hepatopancreatobiliary oncology","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104666","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104666"}}